Company news

Unicycive Therapeutics, Inc. news in 2025

Unicycive Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)

December 29, 2025

Unicycive Therapeutics to Participate in Upcoming Investor Events in December

November 25, 2025

Unicycive Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

November 12, 2025

Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

November 3, 2025

Unicycive Therapeutics Announces Upcoming Presentation of New Data Reinforcing the Potential of Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia at the American Society of Nephrology Kidney Week 2025 Conference

October 30, 2025

Unicycive Therapeutics Provides Update from FDA Type A Meeting and Expects to Resubmit OLC NDA Before Year-End

October 28, 2025

Unicycive Therapeutics to Participate in Upcoming Investor Events in September

August 26, 2025

Unicycive Therapeutics Granted New U.S. Patent for UNI-494 to Treat Chronic Kidney Disease

August 18, 2025

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

August 14, 2025

Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology

July 24, 2025

Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

July 8, 2025

Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference

July 7, 2025

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

June 30, 2025

Unicycive Therapeutics, Inc. Announces Reverse Stock Split

June 17, 2025

Unicycive Provides Update on New Drug Application for Oxylanthanum Carbonate to Treat Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis

June 10, 2025

Unicycive Therapeutics to Present at Upcoming Investor Conferences

May 22, 2025

Unicycive Therapeutics Announces Time Change for 2025 Annual Meeting of Stockholders

May 21, 2025

Unicycive Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

May 14, 2025

Unicycive Presents New Patient-Level Data Underscoring Challenges Faced with Current Phosphate Binders and Highlighting the Potential of Oxylanthanum Carbonate to Address Barriers to Adherence for Patients with Hyperphosphatemia on Dialysis

April 10, 2025

Unicycive Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

April 1, 2025

Unicycive Therapeutics Announces Full Year 2024 Financial Results and Provides Business Update

March 31, 2025

Unicycive to Highlight Patient Reported Outcomes Data at Upcoming Medical Meetings Showing Oxylanthanum Carbonate Reduced Pill Burden and Improved Adherence in Treatment of Hyperphosphatemia

March 13, 2025

Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360

February 20, 2025

Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science

January 27, 2025

Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science

January 6, 2025